Monday, February 5, 2018
Theratome Bio said it plans to begin manufacturing small doses of the experimental drug and start clinical trials on patients in the first half of 2019. The plan is to administer the drugs to 24 patients who are undergoing a transaortic valve replacement, a minimally invasive surgical procedure that repairs the valve. Brain injury is a significant complication of the procedure. The company, formerly known as NeuroFx, had previously raised about $2 million, chiefly from Ambassador Enterprises of Fort Wayne. Theratome Bio, is based at the Indiana Center for Biomedical Innovation at Methodist Hospital downtown with six employees and consultants, . Read Now.